The US FDA has accepted to review Bristol-Myers Squibb Company and Pfizer's Eliquis (apixaban) supplemental new drug application for prophylaxis of deep vein thrombosis (DVT) subsequent to hip or knee replacement surgery. The application ...
Tags: Drug Application, Medicine
Bristol-Myers Squibb has reached an agreement with Reckitt Bencksier for several of its over-the-counter medicines. As part of the agreement, Reckitt Benckiser will pay Bristol-Myers Squibb $438 million (£282 million) upfront for ...
Bristol-Myers Squibb and Pfizer have announced the US FDA's approval for Eliquis (apixaban), used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In 2007, Pfizer and Bristol-Myers ...
Tags: US, FDA, Eliquis, patients, nonvalvular atrial fibrillation
Bristol-Myers Squibb and Pfizer have announced the approval of Eliquis (apixaban) anticoagulant for the prevention of ischemic stroke and systemic embolism in patients suffering from nonvalvular atrial fibrillation (NVAF) in Japan. The ...
Tags: Japan, approval, anticoagulant, subanalysis
The European Commission has cleared an oral anticoagulant, Eliquis, developed by Bristol-Myers Squibb (BMS) and Pfizer. Eliquis 5mg, trade name of apixaban in Europe, is indicated as a twice-daily drug for preventing strokes and systemic ...
Tags: BMS-Pfizer Oral Anticoagulant, oral anticoagulant, Eliquis, apixaban